The (mis)use of psychoactive medicines: Getting the balance right in complex systems

Addiction

Volumn 109, Issue 2, 2014, Pages 182-183

  Griffiths, Paul ^a   Evans Brown, Michael ^a   Sedefov, Roumen ^a  

^a EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Diversion; Medicines; New psychoactive substances; Opioids; Policy; Prescription drug misuse

Indexed keywords

NARCOTIC ANALGESIC AGENT;

DRUG MISUSE; EUROPEAN UNION; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; NORTH AMERICA; OPIATE ADDICTION; ORGANIZATION AND MANAGEMENT;

ANALGESICS, OPIOID; DELIVERY OF HEALTH CARE; EUROPEAN UNION; HEALTH POLICY; HUMANS; NORTH AMERICA; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE;

EID: 84892405657     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12306     Document Type: Note

References (19)

1. Fischer B., Keates A., Bühringer G., Reimer J., Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction 2014; 109: 177-181.
2. Casati A., Sedefov R., Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18: 228-245.
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Harm reduction: evidence, impacts and challenges. Luxembourg: Publications Office of the European Union; 2010.
4. Pauly V., Pradel V., Pourcel L., Nordmann S., Frauger E., Lapeyre-Mestre M. etal. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend 2012; 126: 13-20.
5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA Trendspotter study on fentanyl in Europe. Luxembourg: Publications Office of the European Union; 2012.
6. Griffiths P., Mounteney J., Laniel L. Understanding changes in heroin availability in Europe over time: emerging evidence for a slide, a squeeze and a shock. Addiction 2012; 107: 1539-1540.
7. Uosukainen H., Kauhanen J., Voutilainen S., Föhr J., Paasolainen M., Tiihonen J. etal. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug Alcohol Depend 2013; 127: 207-214.
8. National Records of Scotland. Table Y. Drug-related deaths, on the basis of the Office for National Statistics (ONS) 'wide' definition, by selected drugs reported, 2001-2011. 2012. Available at: http://www.gro-scotland.gov.uk/files2/stats/drug-related-deaths/2011/drug-related-deaths2011.pdf (accessed 10 July 2013) (Archived by WebCite at http://www.webcitation.org/6IzSbcETW).
9. United States General Accounting Office. Prescription drugs: oxycontin abuse and diversion and efforts to address the problem. Washington, DC: United States General Accounting Office; 2003.
10. United States Food and Drug Administration. Risk evaluation and mitigation strategy (REMS) for extended-release and long-acting opioids. 2013. Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm (accessed 10 July 2013) (Archived by WebCite at http://www.webcitation.org/6IzSjRljL).
11. Center for Drug Evaluation and Research. Guidance for industry. Abuse-deterrent opioids-evaluation and labeling. Draft guidance. Silver Spring, MD: Food and Drug Administration; 2013.
12. Cicero T. J., Ellis M. S., Surratt H. L. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367: 187-189.
13. Advisory Council on the Misuse of Drugs (ACMD). ACMD consideration of tramadol. London: Home Office; 2013.
14. Giraudon I., Lowitz K., Dargan P. I., Wood D. M., Dart R. C. Prescription opioid abuse in the United Kingdom. Br J Clin Pharmacol 2013; doi:10.1111/bcp.12133
15. Hawton K., Bergen H., Simkin S., Wells C., Kapur N., Gunnell D. Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study. PLoS Med 2012; 9: e1001213.
16. Gahr M., Freudenmann R. W., Hiemke C., Kölle M. A., Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 2013; 69: 1335-1342.
17. Smith B. H., Higgins C., Baldacchino A., Kidd B., Bannister J. Substance misuse of gabapentin. Br J Gen Pract 2012; 62: 406-407.
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. EMCDDA-Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. Luxembourg: Publications Office of the European Union; 2013.
19. Griffiths P., Evans-Brown M., Sedefov R. Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age. Addiction 2013; doi:10.1111/add.12287